難治性多発性骨髄腫(Refractory Multiple Myeloma):治療薬開発パイプライン動向(世界、2015年上半期版)

Global Markets Directが発行した調査報告書(GMDHC6135IDB)
◆英語タイトル:Refractory Multiple Myeloma - Pipeline Review, H1 2015
◆商品コード:GMDHC6135IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2015年1月30日
◆ページ数:415
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、世界における難治性多発性骨髄腫(Refractory Multiple Myeloma)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・難治性多発性骨髄腫(Refractory Multiple Myeloma)の概要
・難治性多発性骨髄腫(Refractory Multiple Myeloma)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・難治性多発性骨髄腫(Refractory Multiple Myeloma)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・難治性多発性骨髄腫(Refractory Multiple Myeloma)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・難治性多発性骨髄腫(Refractory Multiple Myeloma)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Refractory Multiple Myeloma – Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Refractory Multiple Myeloma – Pipeline Review, H1 2015’, provides an overview of the Refractory Multiple Myeloma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Refractory Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Multiple Myeloma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Refractory Multiple Myeloma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Refractory Multiple Myeloma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Refractory Multiple Myeloma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Refractory Multiple Myeloma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Refractory Multiple Myeloma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Refractory Multiple Myeloma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Refractory Multiple Myeloma Overview 10
Therapeutics Development 11
Pipeline Products for Refractory Multiple Myeloma – Overview 11
Pipeline Products for Refractory Multiple Myeloma – Comparative Analysis 12
Refractory Multiple Myeloma – Therapeutics under Development by Companies 13
Refractory Multiple Myeloma – Therapeutics under Investigation by Universities/Institutes 18
Refractory Multiple Myeloma – Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Refractory Multiple Myeloma – Products under Development by Companies 22
Refractory Multiple Myeloma – Products under Investigation by Universities/Institutes 27
Refractory Multiple Myeloma – Companies Involved in Therapeutics Development 28
4SC AG 28
AbbVie Inc. 29
Acceleron Pharma, Inc. 30
Acetylon Pharmaceuticals, Inc. 31
Actinium Pharmaceuticals, Inc. 32
Altor BioScience Corporation 33
Arno Therapeutics, Inc. 34
Array BioPharma Inc. 35
Astellas Pharma Inc. 36
Astex Pharmaceuticals, Inc. 37
Biotest AG 38
Bristol-Myers Squibb Company 39
Celgene Corporation 40
Cellectar Biosciences, Inc. 41
Chroma Therapeutics Ltd. 42
CureTech Ltd. 43
Curis, Inc. 44
Dicerna Pharmaceuticals, Inc. 45
Exelixis, Inc. 46
F. Hoffmann-La Roche Ltd. 47
GlaxoSmithKline plc 48
Immunomedics, Inc. 49
Johnson & Johnson 50
Karyopharm Therapeutics, Inc. 51
MedImmune, LLC 52
Merck & Co., Inc. 53
Millennium Pharmaceuticals, Inc. 54
MorphoSys AG 55
Novartis AG 56
Oncolytics Biotech Inc. 57
Oncopeptides AB 58
Onyx Pharmaceuticals, Inc. 59
Patrys Limited 60
Pfizer Inc. 61
Pharma Mar, S.A. 62
Pharmacyclics, Inc. 63
Piramal Enterprises Limited 64
Prolexys Pharmaceuticals, Inc. 65
Sanofi 66
Sevion Therapeutics, Inc. 67
Sigma-Tau S.p.A. 68
Solasia Pharma K.K. 69
Stemline Therapeutics, Inc. 70
Sumitomo Dainippon Pharma Co., Ltd. 71
Synta Pharmaceuticals Corp. 72
Threshold Pharmaceuticals, Inc. 73
Vivolux AB 74
Refractory Multiple Myeloma – Therapeutics Assessment 75
Assessment by Monotherapy Products 75
Assessment by Combination Products 76
Assessment by Target 77
Assessment by Mechanism of Action 81
Assessment by Route of Administration 85
Assessment by Molecule Type 87
Drug Profiles 89
4SC-202 – Drug Profile 89
ACP-196 – Drug Profile 91
afuresertib hydrochloride – Drug Profile 93
alisertib – Drug Profile 95
alpelisib – Drug Profile 99
ALT-801 – Drug Profile 101
amrubicin hydrochloride – Drug Profile 103
AR-42 – Drug Profile 105
AT-7519 – Drug Profile 107
AT-9283 – Drug Profile 110
bendamustine hydrochloride – Drug Profile 112
cabozantinib s-malate – Drug Profile 115
CB-5083 – Drug Profile 118
Cell Therapy to Target CD138 for Relapsed and Refractory Multiple Myeloma – Drug Profile 119
CHR-3996 – Drug Profile 120
CUDC-907 – Drug Profile 121
dalantercept – Drug Profile 123
daratumumab – Drug Profile 125
darinaparsin – Drug Profile 128
dasatinib – Drug Profile 130
DCRM-1711 – Drug Profile 133
DKN-01 – Drug Profile 135
elotuzumab – Drug Profile 137
erismodegib – Drug Profile 139
evofosfamide – Drug Profile 142
filanesib – Drug Profile 149
ganetespib – Drug Profile 151
GSK-2857916 – Drug Profile 156
I131-CLR1404 – Drug Profile 157
ibrutinib – Drug Profile 159
indatuximab ravtansine – Drug Profile 165
ixazomib citrate – Drug Profile 167
LCL-161 – Drug Profile 170
LGH-447 – Drug Profile 172
linsitinib – Drug Profile 173
marizomib – Drug Profile 175
MEDI-551 – Drug Profile 177
Melflufen – Drug Profile 179
milatuzumab – Drug Profile 181
MLN-0128 – Drug Profile 183
Monoclonal Antibody Conjugate to Target CD45 for Oncology – Drug Profile 185
MOR-202 – Drug Profile 186
MV-NIS – Drug Profile 188
oprozomib – Drug Profile 190
P-276 – Drug Profile 192
palbociclib – Drug Profile 194
panobinostat – Drug Profile 198
PAT-SM6 – Drug Profile 204
pelareorep – Drug Profile 206
pembrolizumab – Drug Profile 211
pidilizumab – Drug Profile 215
plerixafor – Drug Profile 217
plitidepsin – Drug Profile 219
pomalidomide – Drug Profile 221
PRLX-93936 – Drug Profile 225
Recombinant Protein for Cancer – Drug Profile 227
ricolinostat – Drug Profile 229
SAR-650984 – Drug Profile 231
selinexor – Drug Profile 233
SL-401 – Drug Profile 237
SNS-01T – Drug Profile 239
SST-0001 – Drug Profile 240
trametinib dimethyl sulfoxide + uprosertib – Drug Profile 241
ulocuplumab – Drug Profile 243
vemurafenib – Drug Profile 245
venetoclax – Drug Profile 248
VLX-1570 – Drug Profile 251
vorinostat – Drug Profile 252
Refractory Multiple Myeloma – Recent Pipeline Updates 256
Refractory Multiple Myeloma – Dormant Projects 394
Refractory Multiple Myeloma – Discontinued Products 398
Refractory Multiple Myeloma – Product Development Milestones 400
Featured News & Press Releases 400
Appendix 409
Methodology 409
Coverage 409
Secondary Research 409
Primary Research 409
Expert Panel Validation 409
Contact Us 409
Disclaimer 410

[List of Tables]
Number of Products under Development for Refractory Multiple Myeloma, H1 2015 16
Number of Products under Development for Refractory Multiple Myeloma - Comparative Analysis, H1 2015 17
Number of Products under Development by Companies, H1 2015 19
Number of Products under Development by Companies, H1 2015 (Contd..1) 20
Number of Products under Development by Companies, H1 2015 (Contd..2) 21
Number of Products under Development by Companies, H1 2015 (Contd..3) 22
Number of Products under Investigation by Universities/Institutes, H1 2015 23
Comparative Analysis by Late Stage Development, H1 2015 24
Comparative Analysis by Clinical Stage Development, H1 2015 25
Comparative Analysis by Early Stage Development, H1 2015 26
Products under Development by Companies, H1 2015 27
Products under Development by Companies, H1 2015 (Contd..1) 28
Products under Development by Companies, H1 2015 (Contd..2) 29
Products under Development by Companies, H1 2015 (Contd..3) 30
Products under Development by Companies, H1 2015 (Contd..4) 31
Products under Investigation by Universities/Institutes, H1 2015 32
Refractory Multiple Myeloma - Pipeline by 4SC AG, H1 2015 33
Refractory Multiple Myeloma - Pipeline by AbbVie Inc., H1 2015 34
Refractory Multiple Myeloma - Pipeline by Acceleron Pharma, Inc., H1 2015 35
Refractory Multiple Myeloma - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2015 36
Refractory Multiple Myeloma - Pipeline by Actinium Pharmaceuticals, Inc., H1 2015 37
Refractory Multiple Myeloma - Pipeline by Altor BioScience Corporation, H1 2015 38
Refractory Multiple Myeloma - Pipeline by Arno Therapeutics, Inc., H1 2015 39
Refractory Multiple Myeloma - Pipeline by Array BioPharma Inc., H1 2015 40
Refractory Multiple Myeloma - Pipeline by Astellas Pharma Inc., H1 2015 41
Refractory Multiple Myeloma - Pipeline by Astex Pharmaceuticals, Inc., H1 2015 42
Refractory Multiple Myeloma - Pipeline by Biotest AG, H1 2015 43
Refractory Multiple Myeloma - Pipeline by Bristol-Myers Squibb Company, H1 2015 44
Refractory Multiple Myeloma - Pipeline by Celgene Corporation, H1 2015 45
Refractory Multiple Myeloma - Pipeline by Cellectar Biosciences, Inc., H1 2015 46
Refractory Multiple Myeloma - Pipeline by Chroma Therapeutics Ltd., H1 2015 47
Refractory Multiple Myeloma - Pipeline by CureTech Ltd., H1 2015 48
Refractory Multiple Myeloma - Pipeline by Curis, Inc., H1 2015 49
Refractory Multiple Myeloma - Pipeline by Dicerna Pharmaceuticals, Inc., H1 2015 50
Refractory Multiple Myeloma - Pipeline by Exelixis, Inc., H1 2015 51
Refractory Multiple Myeloma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 52
Refractory Multiple Myeloma - Pipeline by GlaxoSmithKline plc, H1 2015 53
Refractory Multiple Myeloma - Pipeline by Immunomedics, Inc., H1 2015 54
Refractory Multiple Myeloma - Pipeline by Johnson & Johnson, H1 2015 55
Refractory Multiple Myeloma - Pipeline by Karyopharm Therapeutics, Inc., H1 2015 56
Refractory Multiple Myeloma - Pipeline by MedImmune, LLC, H1 2015 57
Refractory Multiple Myeloma - Pipeline by Merck & Co., Inc., H1 2015 58
Refractory Multiple Myeloma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 59
Refractory Multiple Myeloma - Pipeline by MorphoSys AG, H1 2015 60
Refractory Multiple Myeloma - Pipeline by Novartis AG, H1 2015 61
Refractory Multiple Myeloma - Pipeline by Oncolytics Biotech Inc., H1 2015 62
Refractory Multiple Myeloma - Pipeline by Oncopeptides AB, H1 2015 63
Refractory Multiple Myeloma - Pipeline by Onyx Pharmaceuticals, Inc., H1 2015 64
Refractory Multiple Myeloma - Pipeline by Patrys Limited, H1 2015 65
Refractory Multiple Myeloma - Pipeline by Pfizer Inc., H1 2015 66
Refractory Multiple Myeloma - Pipeline by Pharma Mar, S.A., H1 2015 67
Refractory Multiple Myeloma - Pipeline by Pharmacyclics, Inc., H1 2015 68
Refractory Multiple Myeloma - Pipeline by Piramal Enterprises Limited, H1 2015 69
Refractory Multiple Myeloma - Pipeline by Prolexys Pharmaceuticals, Inc., H1 2015 70
Refractory Multiple Myeloma - Pipeline by Sanofi, H1 2015 71
Refractory Multiple Myeloma - Pipeline by Sevion Therapeutics, Inc., H1 2015 72
Refractory Multiple Myeloma - Pipeline by Sigma-Tau S.p.A., H1 2015 73
Refractory Multiple Myeloma - Pipeline by Solasia Pharma K.K., H1 2015 74
Refractory Multiple Myeloma - Pipeline by Stemline Therapeutics, Inc., H1 2015 75
Refractory Multiple Myeloma - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 76
Refractory Multiple Myeloma - Pipeline by Synta Pharmaceuticals Corp., H1 2015 77
Refractory Multiple Myeloma - Pipeline by Threshold Pharmaceuticals, Inc., H1 2015 78
Refractory Multiple Myeloma - Pipeline by Vivolux AB, H1 2015 79
Assessment by Monotherapy Products, H1 2015 80
Assessment by Combination Products, H1 2015 81
Number of Products by Stage and Target, H1 2015 83
Number of Products by Stage and Mechanism of Action, H1 2015 87
Number of Products by Stage and Route of Administration, H1 2015 91
Number of Products by Stage and Molecule Type, H1 2015 93
Refractory Multiple Myeloma Therapeutics - Recent Pipeline Updates, H1 2015 261
Refractory Multiple Myeloma - Dormant Projects, H1 2015 399
Refractory Multiple Myeloma - Dormant Projects (Contd..1), H1 2015 400
Refractory Multiple Myeloma - Dormant Projects (Contd..2), H1 2015 401
Refractory Multiple Myeloma - Dormant Projects (Contd..3), H1 2015 402
Refractory Multiple Myeloma - Discontinued Products, H1 2015 403
Refractory Multiple Myeloma - Discontinued Products (Contd..1), H1 2015 404

[List of Figures]
Number of Products under Development for Refractory Multiple Myeloma, H1 2015 16
Number of Products under Development for Refractory Multiple Myeloma - Comparative Analysis, H1 2015 17
Number of Products under Development by Companies, H1 2015 18
Comparative Analysis by Late Stage Development, H1 2015 24
Comparative Analysis by Clinical Stage Development, H1 2015 25
Assessment by Monotherapy Products, H1 2015 80
Number of Products by Top 10 Targets, H1 2015 82
Number of Products by Stage and Top 10 Targets, H1 2015 82
Number of Products by Top 10 Mechanism of Actions, H1 2015 86
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 86
Number of Products by Top 10 Routes of Administration, H1 2015 90
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 90
Number of Products by Top 10 Molecule Types, H1 2015 92
Number of Products by Stage and Top 10 Molecule Types, H1 2015 92

【掲載企業】

4SC AG
AbbVie Inc.
Acceleron Pharma, Inc.
Acetylon Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc.
Altor BioScience Corporation
Arno Therapeutics, Inc.
Array BioPharma Inc.
Astellas Pharma Inc.
Astex Pharmaceuticals, Inc.
Biotest AG
Bristol-Myers Squibb Company
Celgene Corporation
Cellectar Biosciences, Inc.
Chroma Therapeutics Ltd.
CureTech Ltd.
Curis, Inc.
Dicerna Pharmaceuticals, Inc.
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline plc
Immunomedics, Inc.
Johnson & Johnson
Karyopharm Therapeutics, Inc.
MedImmune, LLC
Merck & Co., Inc.
Millennium Pharmaceuticals, Inc.
MorphoSys AG
Novartis AG
Oncolytics Biotech Inc.
Oncopeptides AB
Onyx Pharmaceuticals, Inc.
Patrys Limited
Pfizer Inc.
Pharma Mar, S.A.
Pharmacyclics, Inc.
Piramal Enterprises Limited
Prolexys Pharmaceuticals, Inc.
Sanofi
Sevion Therapeutics, Inc.
Sigma-Tau S.p.A.
Solasia Pharma K.K.
Stemline Therapeutics, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Synta Pharmaceuticals Corp.
Threshold Pharmaceuticals, Inc.
Vivolux AB

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 難治性多発性骨髄腫(Refractory Multiple Myeloma):治療薬開発パイプライン動向(世界、2015年上半期版)(Refractory Multiple Myeloma - Pipeline Review, H1 2015)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆